← Back to Search

Aromatherapy for Cancer Distress

N/A

Waitlist Available

Led By Andrew Rezvani, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must have received chemotherapy during preparative regimen (single or multi-agent regimen)

Autologous and Allogeneic patients admitted to E1 for planned HSCT

Timeline

Screening 3 weeks

Treatment Varies

Follow Up phase 1 (transplant day +1, +2 or +3), phase 3 (transplant day +3, +4 or +5)

Awards & highlights

Study Summary

This trial will assess whether using an aromatherapy inhaler can help reduce cancer-related distress and improve coping in patients during the early days post-HSCT.

Who is the study for?

This trial is for adult cancer patients who are undergoing bone marrow transplant (HSCT) and have experienced cancer-related distress. Participants must be over 18, speak English, and able to consent. They should not have allergies to lavender or peppermint oils, a history of certain conditions like scleroderma or atrial fibrillation, nor be receiving treatment for germ cell tumors.Check my eligibility

What is being tested?

The study is testing whether using an aromatherapy inhaler with essential oils can help reduce distress and improve coping in patients right after they've had a hematopoietic stem cell transplant.See study design

What are the potential side effects?

Since this trial involves aromatherapy with essential oils such as lavender and peppermint, potential side effects may include allergic reactions or irritation if one has sensitivity to these scents.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have received chemotherapy as part of my treatment preparation.

Select...

I am scheduled for a stem cell transplant at E1.

Select...

I need a stem cell transplant for my blood cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ phase 1 (transplant day +1, +2 or +3), phase 3 (transplant day +3, +4 or +5)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~phase 1 (transplant day +1, +2 or +3), phase 3 (transplant day +3, +4 or +5)

This trial's timeline: 3 weeks for screening, Varies for treatment, and phase 1 (transplant day +1, +2 or +3), phase 3 (transplant day +3, +4 or +5) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Aromatherapy Inhaler Use Log

Change in Attitudes and Beliefs about Complementary and Alternative Medicine Survey

Change in Cancer Behavior Inventory (Brief Form)

+6 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: SOC only then SOC plus Aromatherapy InhalerExperimental Treatment1 Intervention

Participant will receive standard of care pharmacological intervention (SOC) as needed throughout the day. Participants will complete the Standard of Care Pharmacological Intervention Use Log. At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List.

Group II: SOC and Aromatherapy Inhaler then SOC onlyExperimental Treatment1 Intervention

Participant will use the aromatherapy inhaler as needed for up to two (2) hours in the morning and complete the Aromatherapy Inhaler Use Log. At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford Nurse Alumnae, Stanford UniversityUNKNOWN

Stanford UniversityLead Sponsor

2,394 Previous Clinical Trials

17,341,560 Total Patients Enrolled

Andrew Rezvani, MDPrincipal InvestigatorStanford University

Media Library

Aromatherapy Inhaler Clinical Trial Eligibility Overview. Trial Name: NCT05302583 — N/A

Cancer Distress Research Study Groups: SOC and Aromatherapy Inhaler then SOC only, SOC only then SOC plus Aromatherapy Inhaler

Cancer Distress Clinical Trial 2023: Aromatherapy Inhaler Highlights & Side Effects. Trial Name: NCT05302583 — N/A

Aromatherapy Inhaler 2023 Treatment Timeline for Medical Study. Trial Name: NCT05302583 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are enrollees being accepted for this research project?

"According to records on clinicaltrials.gov, this medical research is no longer recruiting participants as of their last edit date (8/8/2022). However, 6 other trials are still enrolling patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Aromatherapy for HSCT Distress

Aubrey Florom-Smith 2023. "Aromatherapy for HSCT Distress". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05302583.